Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the three months ending March 31, 2022 and 2021:

​

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

​

    

2022

    

2021

Revenue

​

​

​

​

​

​

Targadox®

​

$

2,634

​

$

7,199

Ximino®

​

​

967

​

​

2,100

Exelderm®

​

​

704

​

​

1,217

Accutane®

​

​

4,907

​

​

196

Qbrexza®

​

​

7,376

​

​

—

Amzeeq®

​

​

3,466

​

​

—

Zilxi®

​

​

741

​

​

—

Other branded revenue

​

​

1

​

​

7

Collaboration revenue

​

​

577

​

​

800

Revenue – related party

​

 

52

​

 

68

Other revenue

​

​

2,500

​

 

—

Net revenue

​

$

23,925

​

$

11,587